Deep Brain Stimulation for Treatment Resistant Depression
| 适应症 | Major Depressive Disorder |
|---|---|
| 分期 | 不适用 |
| 申办方 | Emory University |
| 状态 | 已完成 |
| 受试者人数 | 37 人 |
| 干预(药物) | Deep Brain Stimulation |
| 开始日期 | 2006年9月 |
| 完成日期 | 2014年1月2日 |
| 结果公布日 | 2020年7月14日 |
摘要
The purpose of this study is to test the safety, efficacy and mechanism of action of subgenual cingulate (Cg25) deep brain stimulation (DBS) for major depression in patients who have not responded to prior antidepressant treatments. Participation in the study will continue for ten years or until the device receives FDA approval for depression. Forty (40) patients will be enrolled in this study.
Change in Hamilton Depression Rating Scale-17 Score
| Deep Brain Stimulation | 23.6 ± 2.9 score on a scale |
|---|---|
| Deep Brain Stimulation | 11.66 ± 2.6 score on a scale |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital